Tuesday, 19 Jun 2018

You are here

Increasing Adverse Events Seen with Higher Disease Activity in Early RA

Researchers in the NEO-RACo Study Group studied adverse events (AEs) in relation to disease activity in patients with early rheumatoid arthritis (RA).

They followed 99 ERA  patients who started intensive treatment with three conventional synthetic DMARDs (csDMARDs) and oral prednisolone, and were randomized to a 6-month induction treatment with infliximab or placebo. AEs were scored and related to disease activity, including the 28-joint disease activity score (DAS28) and remission rates at 12 and 24 months.

These patients averaged 5.4 ± 4.3 AEs (total 331) and 8% (27) experienced severe or serious AE.

24% of AE lead to drug discontinuation that was temporary (n = 52) or permanent (n = 27) .

Far more discontinuations and AEs were seen with increasing tertiles of DAS28 activity.

An overall higher burden of AEs is associated with higher disease activity and lower likelihood of remission in early RA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.

Does RA kill you? Let me count the ways….and what you can do about it

There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.

FDA Approves Low Dose Baricitinib for Rheumatoid Arthritis

The US Food and Drug Administration has approved baricitinib (Olumiant) for use in adults in moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to TNF inhibitors (TNFi). It is not approved for use, nor has it been studied, in children.

FDA Approves Baricitinib 2 mg for Rheumatoid Arthritis

Today the U.S. Food and Drug Administration approved baricitinib (Oluminant) at the lower dose of 2 mg per day for use in adults with with moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to commonly-used treatments known as TNF inhibitors.

Increased Risk of Depression and Anxiety in Rheumatoid Arthritis

Canadian researchers have analyzed population data and shown that the incidence and prevalence of depression, anxiety  and bipolar disorders are elevated in the rheumatoid arthritis (RA) patients compared to a matched population.